Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Gastrointestinal 1Dermatologic 1

Conditions

Non-Melanoma Skin Carcinoma 1

Interventions

Blood Specimen Collection 22Surveys and Questionnaires 19Nivolumab 14Ipilimumab 12pembrolizumab 11Gene Expression Profiling 11Biopsy 10trametinib 9dabrafenib 8Flow Cytometry 8Specimen Handling 7Polymerase Chain Reaction 7Tomography, Optical Coherence 6Therapeutics 6Immunohistochemistry 6Imiquimod 6Amplified Fragment Length Polymorphism Analysis 6Watchful Waiting 5Psychiatric Rehabilitation 5Immunotherapy 5Data Collection 53-ingenyl angelate 5Mohs Surgery 4Microarray Analysis 4Interviews as Topic 4Immunoenzyme Techniques 4Drug Therapy 4Dermoscopy 4sonidegib 3encorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Voriconazole × Dermatologic × Clear all
NCT01480219 2013-03-11

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Pfizer

Completed
467 enrolled 6 charts
Dermatologic

Non-Melanoma Skin Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡